- Home
- GRAN vs MCRB Comparison
GRAN vs MCRB Comparison
Compare GRAN & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRAN
- MCRB
- Stock Information
- Founded
- GRAN 2020
- MCRB 2010
- Country
- GRAN Hong Kong
- MCRB United States
- Employees
- GRAN N/A
- MCRB N/A
- Industry
- GRAN
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- GRAN
- MCRB Health Care
- Exchange
- GRAN NYSE
- MCRB Nasdaq
- Market Cap
- GRAN 129.3M
- MCRB 103.7M
- IPO Year
- GRAN 2025
- MCRB 2015
- Fundamental
- Price
- GRAN $5.41
- MCRB $14.53
- Analyst Decision
- GRAN
- MCRB Hold
- Analyst Count
- GRAN 0
- MCRB 4
- Target Price
- GRAN N/A
- MCRB $73.67
- AVG Volume (30 Days)
- GRAN 396.4K
- MCRB 164.6K
- Earning Date
- GRAN 01-01-0001
- MCRB 08-06-2025
- Dividend Yield
- GRAN N/A
- MCRB N/A
- EPS Growth
- GRAN N/A
- MCRB N/A
- EPS
- GRAN 0.25
- MCRB 8.98
- Revenue
- GRAN $4,731,044.00
- MCRB N/A
- Revenue This Year
- GRAN N/A
- MCRB N/A
- Revenue Next Year
- GRAN N/A
- MCRB N/A
- P/E Ratio
- GRAN $19.39
- MCRB $1.74
- Revenue Growth
- GRAN 17.00
- MCRB N/A
- 52 Week Low
- GRAN $4.30
- MCRB $6.53
- 52 Week High
- GRAN $6.70
- MCRB $29.40
- Technical
- Relative Strength Index (RSI)
- GRAN N/A
- MCRB 66.40
- Support Level
- GRAN N/A
- MCRB $11.15
- Resistance Level
- GRAN N/A
- MCRB $14.78
- Average True Range (ATR)
- GRAN 0.00
- MCRB 1.38
- MACD
- GRAN 0.00
- MCRB -0.05
- Stochastic Oscillator
- GRAN 0.00
- MCRB 72.33
About GRAN GRANDE GROUP LIMITED
Grande Group Ltd is a financial service providers in Hong Kong. It is a financial firm that focuses on providing quality corporate finance advisory services to clients. The company in engage in Type 1 (dealing in securities) and Type 6 (advising on corporate finance) regulated activities in Hong Kong.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.